United Kingdom· GB-APID-31007911000001104
Zerbaxa 1g/0.5g powder for concentrate for solution for infusion vials
A medicinal product containing ceftolozane + tazobactam, registered in United Kingdom by Merck Sharp & Dohme (UK) Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ceftolozane + Tazobactam
- Manufacturer
- Merck Sharp & Dohme (UK) Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 4
- gtin5013945301595
- gtin5013945303902
- gtin00191778008913
- gtin00191778018448
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozane + tazobactam in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
- IcelandZerbaxaMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a38f6dad-7a82-4f8a-be97-b1f0aa0f0f40 GET /v1/drugs/a38f6dad-7a82-4f8a-be97-b1f0aa0f0f40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "31007911000001104",
"desc": "Zerbaxa 1g/0.5g powder for concentrate for solution for infusion vials (Merck Sharp & Dohme (UK) Ltd)",
"form": "Powder for solution for infusion",
"vpid": "31007811000001109",
"source": "dmd",
"vtm_id": "775119009",
"strength": "1 gram",
"substance": "Ceftolozane + Tazobactam",
"ingredient": "Ceftolozane sulfate",
"supplier_code": "39306911000001106"
}See everything about ceftolozane + tazobactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.